HOME >> BIOLOGY >> NEWS
Zengen, Inc. receives patent application approval for proprietary peptide technology

WOODLAND HILLS, Calif. (October 2, 2003) - Zengen, Inc. announced today that the United States Patent Office has approved a patent application for "A Lys-Pro-Val Dimer, Formulations and Applications," which covers novel peptide CZEN 002. This marks the first patent application approval for CZEN 002, with issuance of the patent expected by the end of the year. In addition, Zengen holds multiple patents and patents-pending worldwide on its peptide technologies.

"This development provides further validation of the efficacy of CZEN 002," said R. Steven Davidson, Ph.D., President and CEO of Zengen. "The approved patent application claims are directed to the novel peptide, which has the ability to control infection and/or inflammation associated with, among other disease states, urogenital conditions, including vaginitis."

Zengen is currently conducting Phase I/II clinical trials for CZEN 002, one of the Company's proprietary peptide molecules, for the treatment of vulvovaginal candidiasis, commonly known as vaginal yeast infection. Zengen's peptides have broad applications as anti-inflammatory and anti-infective prescription pharmaceuticals and are based on the larger melanocortin peptide, alpha-Melanocyte-Stimulating Hormone (a-MSH).

About CZEN 002

A synthetic octapeptide, CZEN 002 was developed from more than 25 years of original research in the US, Europe and Asia on peptide molecules derived from alpha-Melanocyte-Stimulating Hormone (a-MSH). There is abundant evidence of the anti-inflammatory and anti-infective activity of CZEN 002 from both in vivo and in vitro research.

Microorganisms (e.g., fungi, bacteria, viruses) cause a host of symptoms by their occupation of vulnerable body sites, overgrowth and subsequent interference with cell metabolism, all of which give rise to a broad range of life-threatening diseases and disorders. In preclinical and clinical studies, CZEN 002 has been shown to directly kill pathologi
'"/>

Contact: Kumiko Hakushi
hakushik@ruderfinn.com
310-479-9929
Zengen
2-Oct-2003


Page: 1 2

Related biology news :

1. Zengen, Inc. announces novel approach to reduce organ rejection
2. UT Southwestern receives $1.78 million grant for obesity research as part of NIH Roadmap initiative
3. Schepens Eye Research Institute receives Roadmap grant to develop center for curing eye diseases
4. Northeastern University receives $12.4 million NSF grant for creation of nanomanufacturing institute
5. Research on carbohydrate metabolism receives historical recognition
6. K-States National Agricultural Biosecurity Center receives $1.3 Million from Department of Defense
7. Berkeley Lab soil scientist Margaret Torn receives Presidential Early Career Award
8. NJIT professor receives Presidential Award for breakthrough research with adult stem cells
9. University of Pittsburgh receives $10 million grant for head and neck cancer
10. LSU Vet School receives $9.9 million for infectious disease research
11. UCSB professor and director receives two national awards

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/19/2020)... ... 2020 , ... Join experts from Envigo Lauren Klaskala, Project Manager ... webinar on Wednesday, July 8, 2020 at 11am EDT (4pm BST/UK). , Nuclease-based ... models. However, while modifying the genome may be more straightforward, the challenge to create ...
(Date:6/5/2020)... ... June 04, 2020 , ... Murrieta Genomics ... new patent application for simplified sample preparation for Next Generation Genomic Sequencing (NGS) ... reduce cost, time, and complexity of sample preparation. , “I have been at the ...
(Date:5/30/2020)... Calif. (PRWEB) , ... May 29, 2020 , ... ... enabler of digital transformation for enterprises globally, has collaborated with EchoNous Inc. to ... FDA. It can measure systolic heart function, which has been clinically tested ...
Breaking Biology News(10 mins):
(Date:7/18/2020)... (PRWEB) , ... July 17, 2020 , ... ... global consulting firm for the life sciences and food industries, is pleased to ... Director of Clinical Research – Business Development. , Charles is an accomplished and ...
(Date:7/10/2020)... ... July 09, 2020 , ... Sentien Biotechnologies, ... the hiring of Allen R. Nissenson, M.D., F.A.C.P., as its Chief Medical Officer. ... of Sentien’s lead product, SBI-101. Dr. Nissenson serves as an Emeritus Professor ...
(Date:7/1/2020)... , ... June 29, 2020 , ... ... to competitively procured purchasing contracts to its membership, recently named BioFit Engineered ... members with the opportunity to purchase ergonomic seating, cafeteria tables, book trucks and ...
(Date:6/28/2020)... HILL, Conn. (PRWEB) , ... June 25, 2020 ... ... company formed to advance photodynamic therapy for treating cancer, today announced the company ... New York (“Roswell Park”). The agreement provides Lumeda globally exclusive rights to ...
Breaking Biology Technology:
Cached News: